reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-30. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
=== 13-31 August 2008 === An anonymous U.S. functionary said: "Saakashvili had always told us he could not stand by while Georgian villages were being shelled, and we always knew this was a point of pressure. We always told him that he should not give in to the kind of provocations we knew the Russians were capable of." In August 2008, Modest Kolerov, former head of the Department for international and cultural ties with foreign countries of the President's Office, admitted that the Kremlin had "a clear plan of action in the case of a conflict", and "the expediency with which the military operation was executed confirms that." Robert Gates, United States Secretary of Defense, said on August 14 that there had been clashes with the South Ossetian forces each August since 2004, but "This year it escalated very quickly and it seemed to me that Russians were prepared to take advantage of an opportunity and did so very aggressively." Zbigniew Brzezinski compared Russia's attack on Georgia to the Soviet attack on Finland and wrote that "Moscow was waiting for such an act to provide a pretext for the use of force." He suggested that Russia could attack Ukraine and other post-Soviet countries were not safe. Ralph Peters, a former military intelligence analyst, and several western diplomats (a western diplomat with contacts with the Georgians and a western mediator acquainted with Saakashvili) said that it was Russia who was provoking Georgia. It was reported that the United States had prevented Saakashvili from taking military action in Abkhazia in early May 2008.
== Pipeline == As of 31 December 2025, the company's pipeline consisted of ten drug candidates covering 14 indications across three platforms. Seven candidates are PDGF-based, with the remainder comprising mRNA, ASO, and Tβ4 candidates. Wound healing indications under development include thermal burns, diabetic foot ulcers (DFUs), fresh wounds, pressure ulcers, radiation ulcers, dry eye syndrome, corneal injury, photodermatitis, alopecia, haemorrhoids, and gastric ulcers.
=== "Ptomaine poisoning" misconception === Ptomaine poisoning was a myth that persisted in the public consciousness, in newspaper headlines, and legal cases as an official diagnosis, decades after it had been scientifically disproven in the 1910s. In the 19th century, the Italian chemist Francesco Selmi, of Bologna, introduced the generic name ptomaine (from Greek ptōma, "fall, fallen body, corpse") for alkaloids found in decaying animal and vegetable matter, especially (as reflected in their names) putrescine and cadaverine. The 1892 Merck's Bulletin stated, "We name such products of bacterial origin ptomaines; and the special alkaloid produced by the comma bacillus is variously named Cadaverine, Putrescine, etc." while The Lancet stated, "The chemical ferments produced in the system, the... ptomaines which may exercise so disastrous an influence." It is now known that the "disastrous... influence" is due to the direct action of bacteria and only slightly due to the alkaloids. Thus, the use of the phrase "ptomaine poisoning" is obsolete. At a Communist Party political convention in Massillon, Ohio, and aboard a cruise ship in Washington, D.C., hundreds of people were sickened in separate incidents by tainted potato salad, during a single week in 1932, drawing national attention to the dangers of so-called "ptomaine poisoning" in the pages of the American news weekly Time. In 1944, another newspaper article reported that over 150 people in Chicago were hospitalized with "ptomaine poisoning", apparently from rice pudding served by a restaurant chain.
== Overview == The first observation of cellular structures resulting from the freezing of water goes back over a century, but the first reported instance of freeze-casting, in the modern sense, was in 1954 when Maxwell et al. attempted to fabricate turbosupercharger blades out of refractory powders. They froze extremely thick slips of titanium carbide, producing near-net-shape castings that were easy to sinter and machine. The goal of this work, however, was to make dense ceramics. It was not until 2001, when Fukasawa et al. created directionally porous alumina castings, that the idea of using freeze-casting as a means of creating novel porous structures really took hold. Since that time, research has grown considerably with hundreds of papers coming out within the last decade. The principles of freeze casting are applicable to a broad range of combinations of particles and suspension media. Water is by far the most commonly used suspension media, and by freeze drying is readily conducive to the step of sublimation that is necessary for the success of freeze-casting processes. Due to the high level of control and broad range of possible porous microstructures that freeze-casting can produce, the technique has been adopted in disparate fields such as tissue scaffolds, photonics, metal-matrix composites, dentistry, materials science, and even food science. There are three possible end results to uni-directionally freezing a suspension of particles. First, the ice-growth proceeds as a planar front, pushing particles in front like a bulldozer pushes a pile of rocks.
== Births == 17 January - William Saunders, poet (died 1851) 1 February - Jane Williams (Ysgafell), writer (died 1885) 9 April - Theophilus Redwood, pharmacist (died 1892) 21 April - Sir George Cornewall Lewis, statesman (died 1863) date unknown Joseph Murray Ince, painter (died 1859) Harry Longueville Jones, archæologist, artist and Inspector of Schools for Wales (died 1870) David Pugh, politician (died 1890) probable - Thomas Rees (Twm Carnabwth), Rebecca rioter (died 1876)
Sources: en.wikipedia.org
single-stranded DNA (ssDNA) Any DNA molecule that consists of a single nucleotide polymer or strand, as opposed to a pair of complementary strands held together by hydrogen bonds (double-stranded DNA). In most circumstances, DNA is more stable and more common in double-stranded form, but high temperatures, low concentrations of dissolved salts, and very high or low pH can cause double-stranded molecules to decompose into two single-stranded molecules in a denaturation process known as melting; this reaction is exploited by naturally occurring enzymes such as those involved in DNA replication as well as by laboratory techniques such as polymerase chain reaction.
=== Junctions and crosslinking === Junctions between two or more nanotubes have been widely discussed theoretically. Such junctions are quite frequently observed in samples prepared by arc discharge as well as by chemical vapor deposition. The electronic properties of such junctions were first considered theoretically by Lambin et al., who pointed out that a connection between a metallic tube and a semiconducting one would represent a nanoscale heterojunction. Such a junction could therefore form a component of a nanotube-based electronic circuit. The adjacent image shows a junction between two multiwalled nanotubes. Junctions between nanotubes and graphene have been considered theoretically and studied experimentally. Nanotube-graphene junctions form the basis of pillared graphene, in which parallel graphene sheets are separated by short nanotubes. Pillared graphene represents a class of three-dimensional carbon nanotube architectures.
=== Medical research relevance === Enzymatic specificity provides useful insight into enzyme structure, which ultimately determines and plays a role in physiological functions. Specificity studies also may provide information of the catalytic mechanism. Specificity is important for novel drug discovery and the field of clinical research, with new drugs being tested for its specificity to the target molecule in various rounds of clinical trials. Drugs must contain as specific as possible structures in order to minimize the possibility of off-target affects that would produce unfavorable symptoms in the patient. Drugs depend on the specificity of the designed molecules and formulations to inhibit particular molecular targets. Novel drug discovery progresses with experiments involving highly specific compounds. For example, the basis that drugs must successfully be proven to accomplish is both the ability to bind the target receptor in the physiological environment with high specificity and also its ability to transduce a signal to produce a favorable biological effect against the sickness or disease that the drug is intended to negate.
=== The Ouagadougou Accords (2013) === To prevent further violence and enable peaceful elections, mediation efforts led by Burkina Faso's President Blaise Compaoré began on June 6, 2013. After 11 days of intense negotiations, an agreement was reached, and the Ouagadougou Accords were signed on June 18, 2013. The signatories included the Malian government, represented by the Minister of Territorial Administration, Colonel Moussa Sinko Coulibaly, and the leadership of the MNLA and the High Council for the Unity of Azawad (HCUA). Key provisions of the agreement included:
Sources: en.wikipedia.org
There are two broad main traditions in cider production in the UK: the West Country tradition and the eastern Kent and East Anglia tradition. The former are made using a much higher percentage of true cider apples and so are richer in tannins and sharper in flavour. Kent and East Anglia ciders tend to use a higher percentage of or are exclusively made from, culinary and dessert fruit; they tend to be clearer, more vinous and lighter in body and flavour. At one end of the scale are the traditional, small farm-produced varieties. These are non-carbonated and usually cloudy orange in appearance. Britain's West Country contains many of these farms which have an abundance of ancient varieties of specialist cider-apples. Production is often on such a small scale, the product being sold only at the site of manufacture or in local pubs and shops. At the other end of the scale are the factories mass-producing brands such as Strongbow and Blackthorn. Mass-produced cider, such as that produced by Bulmers, is likely to be pasteurised and force-carbonated. The colour is likely to be golden yellow with a clear appearance from the filtration. White ciders are almost colourless in appearance and only need contain 25% apple.
== Metabolism == GABA transaminase enzymes catalyze the conversion of 4-aminobutanoic acid (GABA) and 2-oxoglutarate (α-ketoglutarate) into succinic semialdehyde and glutamate. Succinic semialdehyde is then oxidized into succinic acid by succinic semialdehyde dehydrogenase and as such enters the citric acid cycle as a usable source of energy.
If the content of a single indispensable amino acid in the diet is less than the individual's requirement, then it will limit the utilization of other amino acids and thus prevent the normal rates of synthesis even when the total nitrogen intake level is adequate. Thus the "limiting amino acid" will determine the nutritional value of the total nitrogen or protein in the diet. Protein sources, including plants, are thus rated by their limiting amino acids. In any diet, it is critical to consume enough of each essential amino acid. While this is very easy in any diet which consumes meat, a plant-based diet may theoretically miss out on one or more of the essential amino acids, consuming them only in very small quantities. However, in practice, the vast majority of satisfying vegan diets contain more than enough variety in their component foods to meet the minimum requirements of all essential amino acids.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.